Paper42467361
CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.
Liu X and 16 others. MedScience, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation. Papers, record 42467361. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42467361
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Membrane Transport Proteins | Major topic |
| Glioblastoma | Major topic |
| Central Nervous System Neoplasms | Major topic |
| Cholesterol | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Humans | |
| Clustered Regularly Interspaced Short Palindromic Repeats | |
| Disease Progression | |
| Ezetimibe | |
| Anticholesteremic Agents | |
| CD8-Positive T-Lymphocytes | |
| Lymphocyte Activation | |
| Antibodies, Monoclonal, Humanized | |
| Animals | |
| Mice | |
| Disease Models, Animal |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38720342 | Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/38720342 | PubMed |
| 2 | 39329757 | Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets. | Cells | 2024 | https://conductscience.org/library/papers/39329757 | PubMed |
| 3 | 39236712 | Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/39236712 | PubMed |
| 4 | 35189910 | Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. | Mol Cancer | 2022 | https://conductscience.org/library/papers/35189910 | PubMed |
| 5 | 37646615 | Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma. | ACS Nano | 2023 | https://conductscience.org/library/papers/37646615 | PubMed |
| 6 | 31269428 | Macrophages and Metabolism in the Tumor Microenvironment. | Cell Metab | 2019 | https://conductscience.org/library/papers/31269428 | PubMed |
| 7 | 37991252 | Biomimetic Macrophage Membrane-Camouflaged Nanoparticles Induce Ferroptosis by Promoting Mitochondrial Damage in Glioblastoma. | ACS Nano | 2023 | https://conductscience.org/library/papers/37991252 | PubMed |
| 8 | 30622344 | Delivery technologies for cancer immunotherapy. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30622344 | PubMed |
| 9 | 36755314 | Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/36755314 | PubMed |
| 10 | 31848472 | Mechanisms and regulation of cholesterol homeostasis. | Nat Rev Mol Cell Biol | 2020 | https://conductscience.org/library/papers/31848472 | PubMed |
| 11 | 30684591 | CRISPR-Cas9 for cancer therapy: Opportunities and challenges. | Cancer Lett | 2019 | https://conductscience.org/library/papers/30684591 | PubMed |
| 12 | 32348727 | Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids. | Cell Stem Cell | 2020 | https://conductscience.org/library/papers/32348727 | PubMed |
| 13 | 39979966 | Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/39979966 | PubMed |
| 14 | 29230226 | Cholesterol Metabolism in T Cells. | Front Immunol | 2017 | https://conductscience.org/library/papers/29230226 | PubMed |
| 15 | 34261630 | Glioblastoma: clinical presentation, diagnosis, and management. | BMJ | 2021 | https://conductscience.org/library/papers/34261630 | PubMed |
| 16 | 15871634 | Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. | Clin Pharmacokinet | 2005 | https://conductscience.org/library/papers/15871634 | PubMed |
| 17 | 32694690 | Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. | Nat Metab | 2020 | https://conductscience.org/library/papers/32694690 | PubMed |
| 18 | 38971819 | ATP6V0A1-dependent cholesterol absorption in colorectal cancer cells triggers immunosuppressive signaling to inactivate memory CD8+ T cells. | Nat Commun | 2024 | https://conductscience.org/library/papers/38971819 | PubMed |
| 19 | 35023619 | Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. | EMBO Mol Med | 2022 | https://conductscience.org/library/papers/35023619 | PubMed |
| 20 | 23091059 | Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering. | J Biol Chem | 2012 | https://conductscience.org/library/papers/23091059 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42467361
GET https://conductscience.org/api/papers/v1/42467361/references?page=2